There is a high need for oral treatments for atopic dermatitis (AD) that cannot be controlled with local therapy. Both phosphodiesterase (PDE) inhibitors and Janus kinase (JAK) inhibitors are interesting approaches .
PDE4 is involved in the regulation of pro-inflammatory cytokines via the degradation of cyclic adenosine monophosphate. Targeting PDE4 reduces the production of pro-inflammatory mediators in AD and may be an interesting treatment target with a favourable safety profile . Apremilast, an orally available PDE4 inhibitor, is approved for the treatment of adults with moderate-to-severe psoriasis and active psoriatic arthritis. This immune modulator regulates a number of the pro-inflammatory signals involved in AD, including IL-17, IL-22, IL-13, and IL-31 .
A phase 2 study published earlier this year evaluated the treatment effect of 30 mg and 40 mg of apremilast on skin clearance, assessed in EASI percentage change from baseline in ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Rituximab beats mycophenolate mofetil in pemphigus vulgaris Next Article
IL-17A blocker effective in paediatric psoriasis patients »
Table of Contents: EADV 2019
Spotlight on Psoriasis
New Insights in Photoprotection
Rosacea – from new spectrum to new therapy
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.